BioAcyl Corp
BioAcyl Corp |
|
 |
 |
 |
|
Janneh, A. H., Kassir, M. F., Dwyer, C. J., & others. (2021). Alterations of lipid metabolism provide serologic biomarkers for the detection of asymptomatic versus symptomatic covid-19 patients - scientific reports. Sci. Rep. 11(14232), 1–10. Added by: Dr. Enrique Feoli (08/08/2021, 18:41) Last edited by: Dr. Enrique Feoli (08/08/2021, 18:43) |
 |
| Resource type: Journal Article DOI: 10.1038/s41598-021-93857-7 ID no. (ISBN etc.): 2045-2322 BibTeX citation key: Janneh2021 View all bibliographic details  |
Categories: BioAcyl Corp Subcategories: Inmunidad de mucosas Creators: Dwyer, Janneh, Kassir, others Collection: Sci. Rep. |
Views: 2/245
|
| Abstract |
|
COVID-19 pandemic exerts a health care emergency around the world. The illness severity is heterogeneous. It is mostly unknown why some individuals who are positive for SARS-CoV-2 antibodies stay asymptomatic while others show moderate to severe disease symptoms. Reliable biomarkers for early detection of the disease are urgently needed to attenuate the virus{'}s spread and help make early treatment decisions. Bioactive sphingolipids play a crucial role in the regulation of viral infections and pro-inflammatory responses involved in the severity of COVID-19. However, any roles of sphingolipids in COVID-19 development or detection remain unknown. In this study, lipidomics measurement of serum sphingolipids demonstrated that reduced sphingosine levels are highly associated with the development of symptomatic COVID-19 in the majority (99.24{%}) SARS-CoV-2-infected patients compared to asymptomatic counterparts. The majority of asymptomatic individuals (73{%}) exhibited increased acid ceramidase (AC) in their serum, measured by Western blotting, consistent with elevated sphingosine levels compared to SARS-CoV-2 antibody negative controls. AC protein was also reduced in almost all of the symptomatic patients{'} serum, linked to reduced sphingosine levels, measured in longitudinal acute or convalescent COVID-19 samples. Thus, reduced sphingosine levels provide a sensitive and selective serologic biomarker for the early identification of asymptomatic versus symptomatic COVID-19 patients.
|